Chordate Medical Holding AB (publ)

Climate Impact & Sustainability Data (2019, 2019-07 to 2019-09, 2022-01 to 2022-03)

Requires further financing for continued operations.
Markets for the company's products are characterized by demands for clinical evidence and sufficiently good effect and duration of treatment methods.
Sales take time to get started, and public reimbursement within healthcare is a long process without a guaranteed outcome.

The company has received financing through 5 issues during 2019 and one financing, in the form of a directed issue at the beginning of 2020.
The board is continuously working to ensure appropriate financing. This work takes into account the warrants described above.
The board has good hopes that sufficient financing can be obtained to continue operations at the desired pace. However, the financing at the time of submission of this report is not secured, so it cannot be ruled out that sufficient financing could not be obtained.

Requires further financing for continued operations, which may occur in a less favorable market and on less favorable terms than currently anticipated.
Markets for the company's products are characterized by demands for clinical evidence and sufficiently good effect and duration of treatment methods.
Operates in markets with high potential but where sales take time to get started, and where public reimbursement within healthcare is a long process without a guaranteed outcome.

Two directed share issues were conducted during the period, raising SEK 11,000,000 before emission costs. A further share issue is planned.

Frameworks Used: K3

Opened a representative office in Riyadh, Saudi Arabia to expand business in the Gulf Cooperation Council (GCC) region.
Recruited Alain Durante as General Manager for the Saudi Arabian office.

The board has a continuous preparedness to raise additional funding if the pace of expansion or the number of markets increases.

Frameworks Used: K3